Reducing the burden of Sickle Cell Disease (SCD) requires substantial financial and political commitment to improving data-collection, diagnosis, treatment and training – doing so will positively impact the lives of millions of patients and families worldwide – says a new Commission published in The Lancet Haematology journal.
Net sales and earnings significantly above prior year – Dividend increase – Forecast 2024 – Biotech Investments
Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast Drägerwerk AG & Co. KGaA: Preliminary figures 2023: Net sales and earnings significantly above prior
January 16, 2024